Indications And Dose
HIV infection in combination with other antiretroviral drugs ▶BY MOUTH ▶Adult: 600 mg daily in 1–2 divided doses Infection
Source page 706
Loading InternPractice…
Individual generic drug information
Extracted information for Abacavir only.
HIV infection in combination with other antiretroviral drugs ▶BY MOUTH ▶Adult: 600 mg daily in 1–2 divided doses Infection
Source page 706
HIV load greater than 100 000 copies/mL. patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)
Source page 706
Caution—increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.
Source page 706
Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA- B*5701 status not known.
Source page 706
Flavours of oral liquid formulations may include banana, or strawberry.
Source page 706
Extracted information for Abacavir only.
→Appendix 1: abacavir
Source page 706
▶Common or very common Appetite decreased. fever. lethargy ▶Rare or very rare Severe cutaneous adverse reactions (SCARs) ▶Frequency not known Hypersensitivity. weight increased SIDE-EFFECTS, FURTHER INFORMATION Life-threatening hypersensitivity reactions have been reported- characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis. Laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time. Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction).
Source page 706
Manufacturer advises caution in mild impairment; consider avoiding in moderate to severe impairment (no information available).
Source page 706
Manufacturer advises avoid in end- stage renal disease.
Source page 706
Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.
Source page 706
Extracted information for Abacavir only.
There can be variation in the licensing of different medicines containing the same drug. Oral solution EXCIPIENTS: May contain Propylene glycol ▶Ziagen (ViiV Healthcare UK Ltd) Abacavir (as Abacavir sulfate) 20 mg per 1 ml Ziagen 20mg/ml oral solution sugar-free | 240 ml P £55.72 Tablet ▶Abacavir (Non-proprietary) Abacavir (as Abacavir sulfate) 300 mg Abacavir 300mg tablets | 60 tablet P £177.60–£177.61 ▶Ziagen (ViiV Healthcare UK Ltd) Abacavir (as Abacavir sulfate) 300 mg Ziagen 300mg tablets | 60 tablet P £208.95
Source page 706
Extracted information for Abacavir only.
Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment. Patients should be provided with an alert card and advised to keep it with them at all times.
Source page 706
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
600 mg daily in 1–2 divided doses
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 706